menu
    • menu

    Company profile for EpicentRx

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment. Through two complementary technology platforms that each activate and mobilize a different half of the immune system, innate (non-specific) and adaptive (specific) immunity, the company is developing drug candidates that are spe...
    EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment. Through two complementary technology platforms that each activate and mobilize a different half of the immune system, innate (non-specific) and adaptive (specific) immunity, the company is developing drug candidates that are specifically toxic to tumor cells, not normal cells. EpicentRx’s lead program, RRx-001, has been tested in several clinical trials, including an ongoing Phase 3 study in small cell lung cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EpicentRxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11099 North Torrey Pines Road, Suite 160 La Jolla, CA 92037
    Telephone
    Telephone
    (858) 947-6635
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.epicentrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Epicentrx Adapt-001 Oral Presentation: Advanced Tgf? Trap At Asco 2024
    Epicentrx Adapt-001 Oral Presentation: Advanced Tgf? Trap At Asco 2024

    23 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epicentrx-announces-oral-presentation-for-the-most-clinically-advanced-tgf--ligand-trap-adapt-001-at-the-upcoming-2024-asco-annual-meeting-302154736.html

    PR NEWSWIRE
    23 May 2024
    Share Share
    USAN Council & INN Expert Committee Recognizes New Therapeutic nibrozetone
    USAN Council & INN Expert Committee Recognizes New Therapeutic nibrozetone

    06 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/united-states-adopted-name-usan-council-and-international-nonproprietary-names-inn-expert-committee-recognizes-new-therapeutic-class-by-granting-nibrozetone-as-new-generic-name-for-epicentrxs-lead-small-molecule-nlrp3-inhib-301871261.html

    PR NEWSWIRE
    06 Jul 2023
    Share Share
    EpicentRx Presents Updates on its Oncology Clinical Development Programs at ASCO
    EpicentRx Presents Updates on its Oncology Clinical Development Programs at ASCO

    02 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epicentrx-presents-updates-on-its-oncology-clinical-development-programs-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting-301841594.html

    PR NEWSWIRE
    02 Jun 2023
    Share Share
    EpicentRx Receives Fast Track Designation from U.S. FDA for Lead Asset, RRx-001
    EpicentRx Receives Fast Track Designation from U.S. FDA for Lead Asset, RRx-001

    29 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epicentrx-receives-fast-track-designation-from-the-us-fda-for-lead-asset-rrx-001-to-preventattenuate-chemotherapy-and-radiation-treatment-induced-severe-oral-mucositis-301784214.html

    PR NEWSWIRE
    29 Mar 2023
    Share Share
    Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo in Traditionally Checkpoint Inhibitor Non-Responsive Tumors
    Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo in Traditionally Checkpoint Inhibitor Non-Responsive Tumors

    15 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/promising-safety-and-efficacy-signals-from-a-small-phase-1-pilot-study-primetime-with-rrx-001--opdivo-nivolumab-in-traditionally-checkpoint-inhibitor-non-responsive-tumors-301773049.html

    PR NEWSWIRE
    15 Mar 2023
    Share Share
    EpicentRx to Present for PII Trial to Assess Efficacy of RRx-001 vs. regorafenib
    EpicentRx to Present for PII Trial to Assess Efficacy of RRx-001 vs. regorafenib

    20 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epicentrx-announces-presentation-for-phase-2-randomized-active-controlled-multicenter-trial-to-assess-the-safety-and-efficacy-of-rrx-001-vs-regorafenib-in-thirdfourth-line-colorectal-cancer-at-the-2023-american-society-of-clin-301726884.html

    PR NEWSWIRE
    20 Jan 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search